Efinopegdutide vs Survodutide

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicEfinopegdutideSurvodutide
What it is

An oxyntomodulin analogue conjugated by a polyethylene glycol linker to a human IgG4 Fc fragment, also coded HM12525A and JNJ-64565111, according to FDA’s substance registry.1

An investigational glucagon receptor and GLP-1 receptor dual agonist from Boehringer Ingelheim, also known as BI 456906.3,6

FDA status

Not FDA-approved

No FDA approval reported; studied in clinical trials1,2

No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page does not list it.1,2

Is efinopegdutide FDA-approved?

In clinical trials

In clinical trials; not FDA-approved3,4,5

Not FDA-approved. FDA lists survodutide among unapproved drugs it has warned companies for selling with false research-use labels.5

Is survodutide FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.7

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Efinopegdutide is not among them.7,8

Not among the six peptides the policy lists.7

FDA compounding safety-risk page

Not listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list efinopegdutide.2

Not addressed in this profile’s sources.

Kinds of studies cited

Smaller controlled human trials

  • Controlled human trial A phase 2a randomized, active-comparator-controlled, open-label trial in 145 people with non-alcoholic fatty liver disease, in which liver fat fell by 72.7% with efinopegdutide and 42.3% with semaglutide after 24 weeks.9

Large randomized human trials

  • Large randomized human trial SYNCHRONIZE-1, a 76-week blinded, randomized, placebo-controlled Phase 3 trial in 725 adults with obesity, or overweight with a related condition, that excluded diabetes, published in The New England Journal of Medicine.10
  • Large randomized human trial A 46-week randomized, double-blind, placebo-controlled Phase 2 trial that treated 386 adults with overweight or obesity without diabetes, published in The Lancet Diabetes & Endocrinology.6
  • Controlled human trial A 48-week randomized, placebo-controlled Phase 2 trial that treated 293 adults with biopsy-confirmed MASH and liver fibrosis, published in The New England Journal of Medicine.11
  • Controlled human trial SYNCHRONIZE-MASLD, a 48-week blinded, randomized, placebo-controlled Phase 3 trial in 216 treated adults with obesity and fatty liver disease, published in Nature Medicine.12
  • Registered trial without results SYNCHRONIZE-CVOT (NCT06077864), a Phase 3 cardiovascular safety trial in people with overweight or obesity, listed as completed in its August 11, 2026 registry record. Its results are not part of the sources cited here.13
Records collected

9 ClinicalTrials.gov records and 1 PubMed record collected

13 ClinicalTrials.gov records and 4 PubMed records collected

Area of study

Liver9

Metabolic and weight, Liver3

Latest dated events
  1. A phase 2a trial comparing efinopegdutide with semaglutide in fatty liver disease is published.9
  1. FDA’s page on unapproved GLP-1 drugs, which names survodutide among drugs sold with false research-use labels, is updated, as shown by its content-current date.5
  2. Results of the Phase 3 trials SYNCHRONIZE-1 and SYNCHRONIZE-MASLD are published.10,12
  3. Results of Phase 2 trials in obesity and in MASH with fibrosis are published.6,11

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Efinopegdutide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  2. 2
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  3. 3
    BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver · record history version 50 · last update posted 2026-07-22 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026

  4. 4
    ClinicalTrials.gov record NCT07754461 · retained source version 2026-08-10:d71d6065261ae9f1c83fbc9694b2dc6cef63964c1377569876a214c0a75eb88e ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026

  5. 5
    FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  6. 6
    Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial (2024) · PMID 38330987 ↗

    The Lancet Diabetes & Endocrinology · Official source · Source checked November 14, 2026

  7. 7
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  8. 8
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  9. 9
    A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease (2023) · PMID 37355043 ↗

    Journal of Hepatology · Official source · Source checked November 16, 2026

  10. 10
    Survodutide Once Weekly for the Treatment of Adults with Obesity (SYNCHRONIZE-1, 2026) · PMID 42253238 ↗

    The New England Journal of Medicine · Official source · Source checked November 14, 2026

  11. 11
    A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis (2024) · PMID 38847460 ↗

    The New England Journal of Medicine · Official source · Source checked November 14, 2026

  12. 12
    Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial (2026) · PMID 42252333 ↗

    Nature Medicine · Official source · Source checked November 14, 2026

  13. 13
    ClinicalTrials.gov record NCT06077864 · retained source version 2026-08-11:60e24ca2b3858aa7bfd06f0e1cac79051207229d8181cdbe15a0399bddf60984 ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026